Abbott and GSK to Collaborate on Molecular Diagnostic Check Abbott has entered into an agreement with GlaxoSmithKline to build up an automated molecular diagnostic test, predicated on polymerase chain reaction technology, intended to screen non-small cell lung tumor tumors for expression of the MAGE-A3 antigen. GSK’s MAGE-A3 ASCI applicant is currently being evaluated as an adjuvant treatment in resected NSCLC in the Stage III clinical study MAGRIT, the biggest lung cancer treatment study ever conducted sildenafil 100mg . To meet the requirements to get GSK’s MAGE A3 ASCI, patients must have MAGE-A3 expressing NSCLC tumors.
Abbott is certainly a innovator in the advancement and commercialization of companion diagnostics and we’re delighted to collaborate with Pfizer, a leader in tumor therapeutics, on the advancement of a check to identify patients who might benefit from this important compound. .. Abbott to partner with Pfizer to develop a companion diagnostic check for non-little cell lung cancer Abbott announced today that it has entered into an agreement with Pfizer Inc to develop a molecular diagnostic check intended to screen non-small cell lung cancer tumors for the presence of gene rearrangements.